USC has embarked on a collaboration with Autobahn Labs, an accelerator for early-stage drug discovery, to identify and advance cutting-edge scientific findings into new therapies – with a special focus on critical unmet medical needs.
Cingulate prepares for FDA approval for its once-daily ADHD pill – Pharmaceutical Technology
Cingulate is planning to initiate two Phase III trials of CTx-1301 for treating ADHD in paediatric and adolescent patient populations in August 2023. Image Credit:
July 12, 2023